Roquefort Therapeutics (LON:ROQ) Stock Price Down 2.4% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s stock price was down 2.4% during mid-day trading on Monday . The stock traded as low as GBX 1.53 ($0.02) and last traded at GBX 1.60 ($0.02). Approximately 293,295 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 2,004,404 shares. The stock had previously closed at GBX 1.64 ($0.02).

Roquefort Therapeutics Trading Down 2.4%

The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The company has a fifty day simple moving average of GBX 1.57 and a 200-day simple moving average of GBX 1.82. The company has a market capitalization of £2.04 million, a PE ratio of -1.32 and a beta of 0.05.

Insider Buying and Selling at Roquefort Therapeutics

In related news, insider Simon Sinclair bought 72,507 shares of the company’s stock in a transaction on Friday, June 27th. The stock was bought at an average cost of GBX 1 ($0.01) per share, for a total transaction of £725.07 ($973.90). Also, insider Stephen Paul West bought 2,400,000 shares of the company’s stock in a transaction on Friday, July 4th. The stock was bought at an average price of GBX 2 ($0.03) per share, with a total value of £48,000 ($64,472.80). 60.40% of the stock is owned by corporate insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.